Working… Menu

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin´s Lymphoma (NHL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01685008
Recruitment Status : Active, not recruiting
First Posted : September 13, 2012
Last Update Posted : February 23, 2021
Information provided by (Responsible Party):
MorphoSys AG

Brief Summary:
This is an open-label, multicentre study to characterize the safety and preliminary efficacy of the human anti CD19 antibody MOR00208 in adult subjects with relapsed/refractory non-Hodgkin´s lymphoma (NHL) who have received at least 1 prior therapy containing rituximab (at least once).

Condition or disease Intervention/treatment Phase
Non-Hodgkin Lymphoma Drug: MOR00208 (formerly Xmab 5574) Phase 2

Detailed Description:
The study enrols patients from four different NHL subtypes: FL, DLBCL, MCL and other indolent NHL. The study will employ a two-stage design where the decision to further enrol any NHL subtype in stage 2 will depend on best responses after two or three cycles in stage 1.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 92 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IIa, Open-label, Multicenter Study of Single-Agent MOR00208, an Fc-optimized Anti-CD19 Antibody in Patients With Relapsed or Refractory Non-Hodgkin´s Lymphoma (NHL)
Actual Study Start Date : April 23, 2013
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: MOR00208 (formerly Xmab5574)
intravenous Infusion of MOR00208, Fc-Optimized Anti-CD19 Antibody
Drug: MOR00208 (formerly Xmab 5574)
Other Name: MOR208

Primary Outcome Measures :
  1. Overall response rate (ORR) [ Time Frame: up to 4 years ]
    Proportion of Patients with Complete Response (CR) or Partial Response (PR)

Secondary Outcome Measures :
  1. Stable Disease (SD) Rate [ Time Frame: up to 4 years ]
    Proportion of Patients with Stable Disease

  2. Duration of Response (DoR) [ Time Frame: up to 4 years ]
    Time from first CR or PR to first documentation of relapse/progression

  3. Time to Progression (TTP) [ Time Frame: up to 4 years ]
    Time from first dosing until documentation of progression or death due to lymphoma

  4. Progression-free Survival (PFS) [ Time Frame: up to 4 years ]
    Time from first dosing until progression or death due to any case

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. male or female patients ≥ 18 years of age.
  2. histologically-confirmed diagnosis according to REAL/WHO classification, of the following B-cell lymphomas :

    1. FL
    2. MCL
    3. DLBCL
    4. Other indolent NHL (eg, MZL/MALT)
  3. Patients' NHL must have progressed after at least 1 prior rituximab containing regimen.
  4. one site of measurable disease by magnetic resonance imaging (MRI) or computed tomography (CT) scan defined as at least one lesion that measures at least 1.5 × 1.5 cm,


    For patients with MCL only, patients with nonmeasurable disease but evaluable sites (bone marrow, spleen, peripheral blood, gastrointestinal tract) can be enrolled.

  5. Patients who have previously received an autologous stem cell transplantation must be at least 4 weeks post-transplant before study drug administration and must have exhibited a full haematological recovery
  6. discontinued previous monoclonal antibody therapy (except rituximab) or radioimmunotherapy administration for at least 60 days before study drug administration.
  7. off rituximab for at least 14 days before the screening visit and be confirmed to have either no response or have disease progression after rituximab treatment.
  8. Patients with DLBCL had a positive [18F]fluorodeoxyglucose-positron emission tomography (FDG-PET) scan at baseline (Cheson response criteria)
  9. Life expectancy of > 3 months.
  10. ECOG performance status of < 3.
  11. laboratory criteria at screening:

    1. Absolute neutrophil count (ANC) ≥ 1.0 (1000/mm3)
    2. Platelet count ≥ 75 × 109/L without previous transfusion within 10 days of first study drug administration
    3. Haemoglobin ≥ 8.0 g/dL (may have been transfused)
    4. Serum creatinine < 2.0 x upper limit of normal (ULN)
    5. Total bilirubin ≤ 2.0 × ULN
    6. Alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN.
  12. If a female of childbearing potential, a negative pregnancy test must be confirmed before enrolment and use of double-barrier contraception, oral contraceptive plus barrier contraceptive, or confirmation of having undergone clinically documented total hysterectomy and/or oophorectomy, tubal ligation.
  13. If a male, an effective barrier method of contraception must be used during the study and for 3 months after the last dose if the patient is sexually active with a female of childbearing potential.
  14. able to comply with all study-related procedures, medication use, and evaluations.
  15. able understand and give written informed consent and comply with the study protocol.

Exclusion Criteria:

  1. Previous treatment with cytotoxic chemotherapy, immunotherapy, radiotherapy or other lymphoma specific therapy within 14 days before the screening visit or patient has not recovered from side effects of previous lymphoma-specific therapy.
  2. Treatment with a systemic investigational agent within 28 days before the screening visit.
  3. Previous treatment with an anti-CD19 antibody or fragments
  4. Previous allogenic stem cell transplantation.
  5. Known or suspected hypersensitivity to the excipients contained in the study drug formulation.
  6. Clinically significant cardiovascular disease or cardiac insufficiency,cardiomyopathy, preexisting clinically significant arrhythmia, acute myocardial infarction within 3 months of enrolment, angina pectoris within 3 months of enrolment.
  7. Clinical or laboratory evidence of active hepatitis B or hepatitis C 8. History of HIV infection.

9. Any active systemic infection (viral, fungal, or bacterial) requiring active parenteral antibiotic therapy within 4 weeks of study drug administration.

10. Current treatment with immunosuppressive agents other than prescribed corticosteroids (not more than 10-mg prednisone equivalent).

11. Major surgery or radiation therapy within 4 weeks before first study drug administration.

12. Systemic diseases (cardiovascular, renal, hepatic, etc) that would prevent study treatment in the investigator's opinion.

13. History or clinical evidence of central nervous system (CNS), meningeal, or epidural disease, including brain metastasis.

14. Active treatment/chemotherapy for another primary malignancy within the past 5 years 15. Pregnancy or breastfeeding in women and women of childbearing potential not using an acceptable method of birth control.

16. History of noncompliance to medical regimens or patients who are considered potentially unreliable not cooperative

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01685008

Show Show 26 study locations
Sponsors and Collaborators
MorphoSys AG
Layout table for investigator information
Principal Investigator: Kristi Blum, MD Ohio State University
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: MorphoSys AG Identifier: NCT01685008    
Other Study ID Numbers: MOR208C201
2012-002659-41 ( EudraCT Number )
First Posted: September 13, 2012    Key Record Dates
Last Update Posted: February 23, 2021
Last Verified: February 2021
Keywords provided by MorphoSys AG:
B-Cell Non-Hodgkin´s Lymphoma
Fc-optimized Anti-CD19 Antibody
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases